Pentamidine isetionate
Brand names: Pentacarinat
Pentamidine isetionate is an antiprotozoal and antifungal agent used for Pneumocystis jirovecii pneumonia (treatment and prophylaxis), leishmaniasis and early-stage African trypanosomiasis, generally as a second-line option.
Adult dose
Paediatric dose
Dose adjustments
In severely impaired renal function (creatinine clearance <10 ml/min) a dose adjustment is required: for life-threatening Pneumocystis jirovecii pneumonia, 4 mg/kg once daily for 7-10 days, thereafter every 2 days to a total of at least 14 doses; in less severe Pneumocystis jirovecii pneumonia, 4 mg/kg every 2 days; for trypanosomiasis and leishmaniasis the dosing interval should not be less than 48 hours. In mild renal impairment, at least 36 hours should have elapsed between doses.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Figure shown is the SPC treatment dose for Pneumocystis jirovecii pneumonia (4 mg pentamidine isetionate per kg body weight once daily by slow IV infusion over 60 minutes; 14 days is generally sufficient). The SPC applies the adult figures to children: section 4.2 opens 'The following dosage recommendations apply to adults, adolescents, children and infants' and under Paediatric population states 'For infants, children and adolescents, the dosage recommendations given above apply.' No separate paediatric figure is given. Other indications in the same SPC use 3-4 mg/kg (leishmaniasis) or 4 mg/kg (trypanosomiasis) — see adultDose.notes. Verify against a children's formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance
Side effects
- Parenteral, very common: azotaemia; acute renal failure (potentially life-threatening); macroscopic haematuria
- Parenteral, very common: local reactions ranging from swelling, inflammation and pain to induration, abscess formation and muscle necrosis
- Parenteral, common: hypoglycaemia, hyperglycaemia, diabetes mellitus (also persistent), hypomagnesaemia, hyperkalaemia and hypocalcaemia (potentially life-threatening)
- Parenteral, common: hypertension or hypotension (potentially life-threatening), circulatory collapse, flushing; syncope and dizziness
- Parenteral, common: anaemia, leukopenia and thrombocytopenia (potentially life-threatening)
- Parenteral, rare: QT interval prolongation and arrhythmia (potentially life-threatening); pancreatitis (potentially life-threatening); Torsades de Pointes and bradycardia (frequency not known)
- Inhalation, common: cough, dyspnoea, wheezing, bronchospasm (especially in smokers or asthmatics), dysgeusia, nausea
Interactions
- QT-prolonging medicinal products — use pentamidine isetionate with caution during concomitant administration, and in patients at increased risk of cardiac arrhythmias, prolonged QT syndrome, cardiac disease, known ventricular arrhythmias, bradycardia (<50 bpm), or untreated hypokalaemia and/or hypomagnesaemia (stated in SPC section 4.4 cross-referencing section 4.5; section 4.5 itself was NOT retrieved in this fetch, so this list is incomplete)
Clinical monograph
How it works
It interferes with protozoal and fungal nucleic acid and folate metabolism and disrupts mitochondrial function, although its precise mode of action is not fully defined.
Prescribing in practice
- Parenteral use can cause severe hypotension, dysglycaemia (both hypoglycaemia and hyperglycaemia), QT prolongation and acute renal impairment, so administration with the patient lying down and close cardiovascular and metabolic monitoring is essential.
- Nebulised administration is used for Pneumocystis prophylaxis and may provoke bronchospasm, which can be reduced by prior bronchodilator use.
- Doses should be adjusted in renal impairment in line with the SPC and specialist advice.
Monitoring
Monitor blood pressure, blood glucose, renal and hepatic function, electrolytes including potassium and magnesium, full blood count and ECG during therapy.
Counselling the patient
- Stay lying down during and after an infusion because of the risk of a sudden fall in blood pressure.
- Report dizziness, palpitations, or symptoms of low or high blood sugar.
- With the inhaled form, tell the team if you develop wheeze or chest tightness.
Evidence & guidelines
Pentamidine is an established alternative to co-trimoxazole for Pneumocystis jirovecii pneumonia where the first-line agent is unsuitable.
Reference: BHIVA OI guidelines; UKHSA imported infections guidance; WHO leishmaniasis; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023